Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Epicrispr raises $90M to rewrite treatment of rare muscle disease
(3h)
Zydus’ Sentynl pens $475M deal for Mereo’s phase 3-ready rare genetic lung disease drug
(3h)
Aura lays off 20% of workforce, rejigs C-suite amid R&D refocus on eye cancer
(4h)
Abbott teams with Google Health on AI-powered health insights app
(9h)
Regeneron backs $75M series A for antibody upstart Infinimmune
(20h)
‘We are proud to be in the lead’: Vaderis lands $152M for phase 3 study in rare blood vessel disorder
(23h)
ITM neuroendocrine tumor drug spurned by FDA over manufacturing qualms
(1d)
Scholar Rock ditches Novo’s legacy Catalent plant in FDA refiling of SMA drug
(1d)
MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial
(1d)
Jazz pays $820M to buy Actio, adding clinical-stage asset to orchestra of epilepsy therapies
(1d)
BioPharma Dive
Ex-Legend CEO takes helm at biotech startup scouring the globe for drugs
(44m)
Chasing Dupixent, a biotech aims to make better antibody drugs for eczema
(3h)
Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease
(4h)
Trump signs order seeking to upend childhood vaccine schedule
(5h)
Vaderis hauls in $152M to test an AKT-targeting drug
(5h)
Sionna cystic fibrosis drug fails key trial, removing threat to Vertex
(1d)
Jazz to buy rare epilepsy drugmaker in potentially $1.3B deal
(1d)
Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the masses
(1d)
Regulatory operations: The overlooked half of submission readiness
(1d)
‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit
(4d)
Endpoints News
Two health insurers give an AI reality check
(1h)
Lilly paid $2B upfront for vaccine biotechs; Infinimmune raises $75M
(2h)
Hims 'able to move extremely quickly' if FDA greenlights six wellness peptides, CEO says
(3h)
Epicrispr secures $90M after early data on epigenetic FSHD treatment
(4h)
Ex-Legend chief Ying Huang becomes CEO of K2, eyes $250M Series A
(4h)
Vaderis gets $152M to run Phase 3 of rare bleeding disorder treatment
(5h)
Trump directs MMR vaccine to be split in three parts, backs autism claim
(20h)
FDA rejects ITM's radiopharma drug over manufacturing problems
(21h)
Bristol Myers details new $2.3B manufacturing campus in Houston
(22h)
Judge blocks enforcement of WuXi AppTec's designation as Chinese military company
(23h)
BioSpace
FDA rejects ITM Isotope’s radiopharma therapy over manufacturing issues
(3h)
Scholar Rock rejigs approval filing after FDA flags violations at Novo plant
(3h)
After billions in deals, Insilico CEO promises: ‘You haven't seen anything yet’
(4h)
Epicrispr, Infinimmune snag combined $165M in VC cash
(4h)
AbCellera’s menopause medicine ‘sets new efficacy bar’ for hot flashes
(5h)
Silence causes uproar in rare blood cancer space as data sets high bar for competitors
(5h)
Vaderis fuels up with $152M series B to test rare vascular disease in Phase 3
(5h)
Austria’s new growth fund could further bolster its dynamic biotech innovation economy
(9h)
BMS picks Texas for new $2.3B manufacturing campus
(23h)
Sionna’s cystic fibrosis failure is a windfall for Vertex’s blockbuster franchise
(1d)
STAT News
Trump says his executive order should restore trust in vaccines. It does the exact opposite
(10m)
How we know that splitting up the MMR vaccine could be dangerous
(2h)
Trump’s vaccine pivot overshadows food rule
(2h)
We’re reading about an FDA rejection, 340B court battles, and more
(3h)
A RAPID proposal for breakthrough coverage, and nurses push back on AI
(3h)
Skylar Bio kicks off new gene therapy trial for deafness
(4h)
Why is MoonLake Immunotherapeutics scared of releasing data on its drug candidate?
(8h)
Nurses seek a seat at the table as they fight expanding clinical AI
(8h)
Burdensome Medicare GLP-1 program may keep patients from accessing $50 per month weight loss drugs
(8h)
The new geography of abortion care
(8h)
BioPharma Trend
Seven HealthTech Trends In Europe To Watch
(1mo)
Self-Care Is Not a Product, It’s Critical Infrastructure: Why We Must Work Together to Make Health Systems Resilient.
(1mo)
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio launch ADME-One, a packaged ADME service for hit identification
(2mo)
AI Won't Replace Clinical Programmers. It Will Split Them Into Two Groups.
(3mo)
Novo Nordisk and OpenAI Team Up to Integrate AI from Discovery to Supply Chain
(4mo)
Life Biosciences Gets $80M as Cellular Rejuvenation Enters the Clinic
(4mo)
Jeito Closes €1B Fund, Europe's Largest Independent Biopharma Raise
(4mo)
Anthropic Pays $400M for an AI Biotech With Fewer Than Ten People
(4mo)
Epia Neuro Wants to Decode Brain's Movement Intentions After Stroke
(4mo)
Generare Raises €20M to Explore Uncharacterized Chemical Space from Microbial DNA
(4mo)
Drug Channels
The K-Shaped Pharmacy Shakeout: Consolidation in Cities, Lost Access in Rural America
(6h)
Informa Connect’s Medicaid Drug Rebate Program Summit
(1d)
A System of Record, or a System of Learning?
(4d)
Who Will Pay for Prescription Drugs in 2034? Medicare's Surprising Rise in the Latest Government Forecasts
(1w)
The Industry Doesn't Have an Access Collaboration Problem. It Has an Accountability Problem.
(2w)
Drug Channels News Roundup, Mid-July 2026: Biosimilar Launch Strategy, Part D Spending Trends, Rural 340B Hospitals, What Employers Can Do About 340B, and Drug Channel Villains
(2w)
Direct-to-Patient: Transforming the Manufacturer Access Model
(3w)
2025 Gross-to-Net Realities at Eight Top Drugmakers: The Net Pricing Drug Channel Emerges
(3w)
2025 Gross-to-Net Realities at Eight Top Drugmakers: The Net Pricing Drug Channel Emerges
(3w)
Direct-to-Consumer Shouldn't Always Mean Direct-To-Mail-Order: Why Fulfillment Choice Matters
(4w)
European Biotechnology Magazine
Swedish kiss for french Innate: Sobi backs Innate’s lacutamab as rare T-cell lymphoma program enters Phase 3
(1d)
Clinical Development Expert has started
(4d)
Actimed retrieves ALS drug after Faraday collapse
(5d)
Mironid lands $46M Series B to take kidney drug into clinic
(5d)
Evexta pairs ex-Merck drug with Roche’s giredestrant
(1w)
AstraZeneca taps Pathos for breast cancer degrader
(1w)
Ipsen quietly returns cancer drug IPN01194 to AGV Discovery
(1w)
Sobi’s dealmaker CEO exits after global expansion
(1w)
AstraZeneca explores $400B combination with BMS
(1w)
ZEUS failure clouds future of Novo’s cardiovascular plans
(2w)
Drug Hunter
Rethinking ERα Degradation as the Driver for SERD Efficacy
(1h)
oveporexton (TAK-861)
(4d)
Regioselective Synthesis of N-Aryl Pyrazoles Stemming from an Academic-Industrial Collaboration
(5d)
BI-3406
(6d)
aleniglipron/GSBR-1290
(1w)
Are RIPTACs the Small Molecule Answers to ADCs?
(1w)
June 2026
(1w)
June 2026 Patent Gazette
(2w)
ensitrelvir (S-217622)
(2w)
BMS CAMK2 Inhibitor Patents Show a Continuing Paradigm Shift from Isoform Selectivity to Tissue Selectivity
(2w)
Labiotech.EU
Seven biotechs driving progress in Duchenne muscular dystrophy
(3h)
We asked 19 biotech leaders what breaks their deals. It wasn’t the science.
(1d)
Top biotech deals in July 2026
(4d)
Why Western pharma is sleeping on China’s circular RNA revolution
(4d)
The biggest biotech funding rounds in July 2026
(6d)
Eight CAR-T companies tackling autoimmune disorders
(1w)
Cryopreservation in cell therapy: Reducing variability from the start
(1w)
10 biotechs in Japan to watch in 2026
(1w)
Merck after Keytruda: what the pipeline looks like
(2w)
Gain Therapeutics: a first-in-class, disease-modifying therapy for Parkinson’s
(2w)
Bio IT World
A Brain Orchestra … Playing at a Range of Unsynchronized Tempos
(11h)
New CEO for PacBio, Updated Chemistry for Vega System
(4d)
‘Reproductive Resilience Hypothesis’ Highlights the Ovary as a Discovery Source in Longevity Research
(5d)
Trends from the Trenches: Why Semantics Matter in Life Sciences
(6d)
Vibrating Capsule Reveals Gut-Brain Biomarkers for Anorexia Relapse
(1w)
Beyond Sequence: Building the Next Generation of Structural Genomics Platforms
(2w)
Follow the Money: Fresenius Expands Multiple Growth Areas, Off-the-Shelf CAR-T Therapies, Antibody for Full Season Influenza
(2w)
Baylor College Serves as Sequencing Center, Immunai, Boehringer Ingelheim Multi-Project Collaboration, Spatial Biology
(2w)
The Most Expensive AI Mistake in Biotech Isn’t a Hallucination, It’s a Process Failure
(3w)
In Vivo CRISPR Therapy is One Step Closer to the Clinic
(3w)
GEN News
Indiana Emerges as a Leading U.S. Biopharma Hub
(3h)
How South Carolina Became the Southeast’s Fastest Growing Biotech Hub
(4h)
The Future of Aging Research Is Longitudinal, Multiomic, and Single-Cell
(4h)
Greater Richmond’s Pharma Cluster Keeps Compounding
(4h)
BMS Chooses Houston for $2.3B Manufacturing Facility
(16h)
Bacterial Trait-Finding and Gene Mapping Platform Speeds Microbial Engineering for Biotech Applications
(19h)
Spatial Transcriptomics Uncovers Heterogeneity in Heart Transplant Rejection
(19h)
Candida auris Persists in Hair Follicles, Hijacks Immune Signaling
(22h)
BaseMap ABE Launched for Off-Target Characterization in Base Editing Therapeutic Development
(1d)
Early-Life Stress Leaves Epigenetic “Scars” That Prime Stress Sensitivity
(1d)
Cure Today
Text a Survivor: Sally Kalksma on Life With Multiple Myeloma
(1h)
Weekly App Check-Ins Eased Fatigue in Metastatic Breast Cancer
(3h)
Divesiran Eliminates Need for Phlebotomy in 88% of Patients With Polycythemia Vera
(20h)
Cyclosporiasis Cases Top 6,700: What Patients with Cancer Need to Know
(21h)
When the Oncology Doctor Who Watched Over You Is Two Hours Away
(21h)
Oncology Nurse Earns Patient Trust Through Clinical Skill and Compassion
(1d)
Dr. Priscilla Merriam Explains Why Sarcomas Are Often Mistaken for Benign Growths
(1d)
"No One Should Be Alone": A Lung Cancer Advocate's Mission to Keep Her Father's Memory Alive
(2d)
Multiple Myeloma Survivor Valerie Traynham: "Survivorship Starts the Moment You Hear, 'You Have Cancer'"
(3d)
Questions to Ask Before Thyroid Cancer Surgery
(3d)
Contract Pharma
Altasciences Expands Bioanalytical Labs in North America
(3h)
Cambrex Breaks Ground on $30M Milan R&D Facility
(3h)
BMS to Build $2.3B Manufacturing Campus in Houston
(1d)
Bruker Invests in Organ-on-a-Chip Firm Mimetas
(1d)
Scinai Appoints Eran Kuratz as Head of Supply Chain & Business Process Administration
(1d)
Innovent Adds Vanflyta to China Oncology Portfolio
(1d)
Jones Healthcare Group Acquires Ontario Thermoforming Facility
(4d)
Biogen Completes RayThera Acquisition
(4d)
The Friday Brief for August 7, 2026: Mergers, Launches, and Rebrands
(4d)
AstraZeneca, CSPC Establish New Biologics Manufacturing JV in China
(4d)
Pharma Times
Lexeo wins FDA RMAT status for LX2020
(7h)
EHP Awards 2027 open for entries
(7h)
NICE backs new blood cancer regimens
(1d)
Obsidian begins registration cohort for amsoki-cel
(1d)
Entera Bio data selected for ASBMR plenary session
(4d)
NHS backs delayed‑release treatment for cystinosis
(5d)
Oblenio doses first patients in phase 1a autoimmune trial
(6d)
BeOne Medicines secures UK innovation passport for HCC therapy
(6d)
Sanofi’s MenQuadfi approved for EU infants
(1w)
Qnovia licenses novel antimicrobial peptide
(1w)
Medcity News
From Friction to Fix: Measuring What’s Breaking Payer-Provider Trust
(3h)
Which Health Tech Companies Are Getting Customer Experience Right?
(4h)
How CMS Is Tackling ‘Coverage Purgatory’ for Medical Devices
(17h)
Amazon Pharmacy Executive: Formularies are Anti-Choice
(17h)
Small Businesses Could Face Double-Digit Premium Hikes in 2027
(17h)
Jazz Pharma Expands Again in Epilepsy With $850M Actio Bio Acquisition
(18h)
MedCity Pivot: How Aetna is Adopting Agentic AI
(23h)
AI in Drug Development is Not a Data Problem — It’s An Evidence Problem
(1d)
How to Keep Clinicians Satisfied, the Ascension Way
(1d)
Compliance Alone Won’t Fix the Home Health Fraud Problem
(1d)
Chemical & Engineering News
Chemistry advances when disciplines connect
(4h)
Periodic Graphics: Caterpillars vs. plants: A chemical battle
(20h)
Memory Lane: Laboratory science before safety data sheets
(21h)
Editorial: Scientific self-governance works well. Let’s not risk it
(1d)
Obituary: John Worns
(1d)
Comment: The ACS Heroes of Chemistry program turns 30
(1d)
New screening platform expands the search for molecular glues
(1d)
Lowest-ever Rhine levels disrupt chemical production
(3d)
Iran conflict lifts chemical earnings
(4d)
Policy Watch: US approves first mRNA flu vaccine
(4d)
The Pharma Letter
CellProthera inks MoU for ProtheraCytes distribution in Japan
(2h)
Long-acting therapies continue to gain momentum in HIV
(4h)
FDA rejects ITM’s ¹⁷⁷Lu-edotreotide filing
(5h)
Pharma as its own retailer
(5h)
Silence Therapeutics' siRNA hits the mark in polycythemia vera
(6h)
Silence Therapeutics' siRNA hits the mark in polycythemia vera
(6h)
Silence Therapeutics' siRNA hits the mark in polycythemia vera
(6h)
MoonLake's nanobody clears Phase III test, but shares slip
(6h)
Avere Thera plans $500M placement to support AVR-001 development
(6h)
Avere Thera plans $500M placement to support AVR-001 development
(6h)
Targeted Oncology
Myeloma Physicians Consider Approaches to Subcutaneous Therapy
(56m)
Ravi Salgia, MD, PhD, Discusses the ADAPT-Funded IMMUNO-BIOMAP Trial in NSCLC
(3h)
Dr Salgia on Curing Advanced Non–Small Cell Lung Cancer
(18h)
FDA Advisory Committee to Review Galleri MCED Test's PMA Application
(23h)
What Biomarkers to Test for in Non–Small Cell Lung Cancer?
(1d)
Adding Ibrutinib to Liso-Cel Drives Deep Remissions in R/R CLL/SLL
(1d)
What the ENDURANCE Trial Reveals About Discontinuing Lenalidomide in Myeloma
(1d)
KRAS-Mutant Lung Cancer: Unmet Needs Persist Beyond G12C, Expert Says
(1d)
Why ePROs Are the Future of Supportive Oncology Care
(2d)
AI Model Predicts Late Distant Recurrence Risk in HR-Positive Breast Cancer
(2d)
MedWatch
Eli Lilly faces criticism for Danish new campaign
(3h)
Novo Nordisk launches once-weekly insulin treatment in the US
(4h)
Eli Lilly maintains plans for production facilities in Germany despite billion-dollar cuts
(7h)
Watch Media launches new media about the Nordic defence industry
(7h)
Covert Novo Nordisk-Lundbeck alliance recruits former Novo candidate and replaces CEO
(8h)
Genmab CEO ahead of legal battle with partner AbbVie: "I'm neither shocked nor intimidated"
(10h)
Eli Lilly's weight-loss tablet gets UK approval
(1d)
Novo Nordisk partners with Amazon to develop drugs faster using AI
(1d)
Chemometec signs collaboration deal with Roche Diagnostics
(1d)
Genmab is setting up sales teams despite lack of data for drug candidates
(1d)
In The Pipeline
So How Is AI Drug Discovery Doing, Really?
(18h)
This Is Why We Run Trials, Unfortunately
(3d)
Put Your Money Down, They Say
(4d)
Target Practice on the Molecular Scale
(5d)
We Only Know Her as Mei
(6d)
The Gut Microbiome and Cancer Therapy
(1w)
A Friendlier Fluorination
(1w)
Bacteria and Cancer: The Latest Word
(2w)
Flatworms, Ion Channels, and Burning Mouths
(2w)
Preventing Misfolding by Preventing Folding
(2w)
Pharmaphorum
England close to eliminating hep C thanks to treatment drive
(6h)
Trump order upturns federal childhood vaccines policy
(7h)
UK is first European country to approve Lilly's Foundayo
(8h)
Ex-BioNTech execs launch 'AI-native' cancer company
(23h)
Tenax trounced by phase 3 heart failure readout
(1d)
Jazz builds in epilepsy with $1.3bn Actio acquisition
(1d)
Novo Nordisk partners Amazon on London AI hub
(1d)
Alzheimer's patients 'not changing brain health behaviours'
(1d)
Sobi adds rare lymphoma drug with $580m Innate tie-up
(1d)
Quartet of biotechs join Nasdaq after stellar IPOs
(1d)
Drug Discovery Weekly
Wegovy pill could help patients lose 17% body weight
(1mo)
How AskBio is pioneering ‘transformative genetic therapies’ in Parkinson’s disease
(1mo)
Webinar: Learn how to accelerate the early stages of drug discovery
(1mo)
Therapy enables 89% survival rate in myeloma patients
(1mo)
Ulcerative colitis treatment shows best-in-class potential
(1mo)
UK patients to benefit from approval of weight loss tablet
(1mo)
Vertex presents new data on Casgevy in children
(1mo)
DDW Highlights: 16 June 2026
(1mo)
LXR inverse agonist shows promise in liver disease
(1mo)
Guide: One solution – from R&D, to QC
(1mo)
HIT Consultant
Why Digital Health Founders Should Stop Worrying if They Are “AI Enough”
(12h)
From “Maybe” to Baltic Gods: The Stories Behind Virus Names
(12h)
Kyndryl to Acquire Healthcare IT Leaders: Scaling AI Modernization Across Hospitals and Payors
(17h)
Redesign Health Study: 71% of Health Systems Adopt an “Epic-First” AI Purchasing Strategy
(23h)
Beyond Pack-Years: Why Lung Cancer Detection Demands a Shift to AI-Driven Case-Finding
(1d)
The Silent Breakdown of Revenue Cycle Management
(1d)
HealthSnap Secures $25M to Scale AI-Augmented Virtual Care
(1d)
CliniComp Receives FDA 510(k) Clearance for EHR-Integrated PACS Viewer
(1d)
iRhythm to Acquire VitalConnect for $287.5M to Build Broad Cardiac Intelligence Platform
(1d)
Three Essential Principles for Evaluating Healthcare AI Vendors
(4d)
Insights: Pink Sheet
New EU Tool Helps Drug Developers Check If They Need A Joint Clinical Assessment
(42m)
UCB Gets Scottish Funding For Zilbrysq, But England’s NICE Not Convinced
(48m)
UK MHRA Sets Diversity Goal For ‘Western Authority Dominated’ PIC/S Pharmacovigilance Group
(2h)
Trump Orders Overhaul Of Childhood Vaccination Schedule, Calls For MMR Split
(7h)
DEA Proposes Down-Scheduling Some Insomnia Drugs, Denies Idorsia Bid To Eliminate Restrictions
(19h)
Tonix Advances Lyme Antibody as Infection-Associated Chronic Illness Gains Interest
(19h)
Generic User Fee Deals Creates Domestic-Focused Incentives, Could Lower Application Fees
(22h)
Global Inspectors Prepare For AI-Powered Pharmacovigilance Era Under PIC/S
(1d)
EMA Explains Shortage Prevention Plan Rules Under Pharma Reform & Critical Medicines Act
(1d)
India Raises Stakes: Fabricated Drug Data Now Risks Permanent Market Exclusion
(1d)
BioXconomy
DOJ adopts targeted approach to mergers
(1h)
RNA and ethical quandaries in Spider-Man: Brand New Day
(1h)
CMS, HRSA target 340B with new payment, rebate rules
(2h)
Innate Pharma lands $580m Sobi partnership for lymphoma therapy
(2h)
Epicrispr raises $90m to advance muscular dystrophy therapy
(4h)
In perfect harmony: Jazz tunes up epilepsy portfolio with $820m Actio deal
(6h)
Medicare’s GLP-1 Bridge program redraws the weight management pricing map
(14h)
Spain continued to lead the EU in clinical trials in 2025, AEMPS reports
(23h)
FDA approves Moderna’s flu shot in first for mRNA vaccines
(1d)
Tarsus expands eye care empire with $800m Alkeus buy
(1d)
BioCentury
FIH urgency in the U.S. Plus: federated learning, biotech IPOs — a BioCentury podcast
(16h)
Jazz expands neuro reach with rare epilepsy takeout: Deals Report
(17h)
Auchincloss bill would embed trials in routine care, speed FIH starts
(17h)
Silence, AbCellera emerge as best-in-class contenders as Sionna sinks
(18h)
WuXi AppTec wins preliminary injunction in 1260H case
(2d)
Mirati vet Christensen named CEO of well-funded start-up Terremoto
(3d)
Four biotechs raise over $1.2B in strong IPO run: Public Equity Report
(3d)
FDA regulatory moves reflect a steadying ship
(3d)
Otsuka’s Voyxact raises the bar in IgA nephropathy
(3d)
Biotech in the balance: A conversation with Jeremy Levin
(4d)
SCRIP
Europe May Follow France’s Biosimilar Lead, Germany Reforms Cut Both Ways: Lupin CEO
(7h)
Stock Watch: Why Investors Sold Sanofi Despite The Headline Beat
(7h)
Tenax Sees A Path Forward For TNX-103 Despite Phase III LEVEL Miss
(19h)
Silence Makes Noise With Positive Divesiran Results In Polycythemia Vera
(19h)
Jazz Returns To Epilepsy Dealmaking With Actio Acquisition
(20h)
Pipeline Watch: Three Approvals And Two Phase III Readouts
(1d)
Quick Listen: Scrip’s Five Must-Know Things
(1d)
Braveheart, Latigo, BlossomHill Perform Well In Public Market Debuts
(3d)
Deal Watch: Tarsus Seeks Another Ophthalmology Buy With Alkeus Takeout Bid
(3d)
SMID Cap Earnings In Brief: Sarepta, Arcturus, Iovance, BioMarin, Viridian & Roivant
(3d)